InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,455.87
(
-0.32%
)
US TECH 100
19,226.80
(
-0.17%
)
Dow Jones
39,083.39
(
-0.13%
)
Brent Oil
85.03
(
0.02%
)
Bitcoin
63,538.10
(
-1.98%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: Whosetosay post# 34179

Friday, 09/13/2013 11:08:53 PM

Friday, September 13, 2013 11:08:53 PM

Post# of 80490
About 20% present T315I in TKI-naive...

When randomized 50/50 this automatically reduces imatinib's MMR by half, or 10%, versus Pona. This also increases Pona's MMR by 7.5% since 75% of T315I patients achieved MMR in PACE trial.

So automatic 17.5% delta on MMR, and as you say throw in a few more of the 49 additional mutations shown to be resistant to imatinib but sensitive to Ponatinib and voila...its EPIC!







Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up